Eli Lilly and Co (NYSE:LLY)

86.82
Delayed Data
As of 4:01pm ET
 +0.71 / +0.82%
Today’s Change
73.69
Today|||52-Week Range
89.09
+2.79%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$90.2B

Company Description

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. It operates through two segments: Human Pharmaceutical Products and Animal Health. The Human Pharmaceutical products segment includes the discovery, development, manufacturing, marketing and sales of human pharmaceutical products worldwide in the following therapeutic areas: neuroscience, endocrinology, oncology, cardiovascular and other. The Animal health segment operating through the Elanco Animal Health division, develops, manufactures, and markets products for both food and companion animals. The Animal health products include Rumensin, Tylan, Posilac, Paylean and other products for livestock and poultry, as well as Trifexis, Comfortis, and other products for companion animals. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.

Contact Information

Eli Lilly & Co.
Lilly Corporate Center
Indianapolis Indiana 46285
P:(317) 276-2000
Investor Relations:

Employees

Shareholders

Mutual fund holders39.13%
Other institutional27.78%
Individual stakeholders11.86%

Top Executives

David A. RicksChairman, President & Chief Executive Officer
Thomas F. BumolSenior VP-Biotechnology & Autoimmunity Research
Michael R. MeadowsVP & Chief Technology Officer
Aarti ShahChief Information Officer & SVP-IT
Timothy J. GarnettChief Medical Officer & VP-Global Medical